Nalaganje...

Requiring an amyloid-β(1-42) biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials

BACKGROUND: Low cerebrospinal fluid (CSF) amyloid-β(1-42) concentration and high total-tau/Aβ(1-42) ratio have been recommended to support the diagnosis of prodromal Alzheimer’s disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and also to select patients for clinical trials. M...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Schneider, Lon S., Kennedy, Richard E., Cutter, Gary R.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2947209/
https://ncbi.nlm.nih.gov/pubmed/20813339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2010.07.004
Oznake: Označite
Brez oznak, prvi označite!